Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038454 (
stroke
)
147,016
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background and Purpose- A growing body of evidence indicates genetic components play critical roles in moyamoya disease (MMD). Firm conclusions from studies of this disease have been stymied by small sample sizes and a lack of replicative results. This meta-analysis was conducted to determine whether these genetic polymorphisms are associated with MMD. Methods- PubMed, Google Scholar, Embase, Wanfang, Web of Science, and China National Knowledge Infrastructure databases were used to identify potentially relevant studies published until January 2020. The Review Manager 5.2 and Stata 15.0 software programs were used to perform the statistical analysis. Heterogeneity was assessed using the Cochran
Q
test and quantified using the
I
2
test. Results- Four thousand seven hundred eleven MMD cases and 8704 controls in 24 studies were included, evaluating 7 polymorphisms in 6 genes. The fixed-effect odds ratios (95% CI) in allelic model of
MMP-2
rs243865 were 0.60 (0.41-0.88) (
P
=0.008). In the country-based subgroup analysis, the fixed-effect odds ratios (95% CI) of
RNF213
rs112735431 in allelic model were China, 39.74 (26.63-59.31), Japan, 74.65 (42.79-130.24) and Korea, 50.04 (28.83-86.88; all
P
<0.00001). In the sensitivity analysis, the fixed-effect odds ratios (95% CI) of allelic and dominant models were the
RNF213
rs148731719 variant, 2.17 (1.36-3.48;
P
=0.001), 2.20 (1.35-3.61;
P
=0.002), the
TIMP-2
rs8179090 variant, 0.33 (0.25-0.43;
P
<0.00001), 0.88 (0.65-1.21;
P
=0.440) and the
MMP-3
rs3025058 variant, 0.61 (0.47-0.79;
P
=0.0002), 0.55 (0.41-0.75;
P
=0.0001), respectively. Conclusions-
RNF213
rs112735431 and rs148731719 were positively, and
TIMP-2
rs8179090,
MMP-2
rs243865, and
MMP-3
rs3025058 were inversely associated with MMD using multiple pathophysiologic pathways. Studies in larger population should be conducted to clarify whether and how these variants are associated with MMD.
Stroke
2020 06
PMID:Association of Genetic Variants With Moyamoya Disease in 13 000 Individuals: A Meta-Analysis. 3239 May 55
A strong therapeutic target of ischemic
stroke
is controlling brain inflammation. Recent studies have implicated the critical role of C-C chemokine receptor 5 (CCR5) in neuroinflammation during ischemic
stroke
. It has been reported that the expression of the matrix metalloproteinases,
MMP-3
, MMP-12, and MMP-13, is controlled by CCR5; however, their expressional regulation in the infarct brain has not been clearly understood. This study investigated the mRNA expression of Mmp-3, -12, and -13 in the ischemic cerebral cortex of photothrombosis mouse model. The three Mmps were highly upregulated in the early stages of ischemic
stroke
and were expressed in different types of cells. Mmp-3 and Mmp-13 were expressed in blood vessel endothelial cells after ischemia-induction, whereas Mmp-12 was expressed in activated microglia. The expression of Mmp-13 in resting microglia and in neurons of uninjured cerebral cortex was lost in the infarct region. Therefore, the MMPs responding to CCR5 are differentially regulated during ischemic
stroke
.
...
PMID:Induced mRNA expression of matrix metalloproteinases Mmp-3, Mmp-12, and Mmp-13 in the infarct cerebral cortex of photothrombosis model mice. 3298 31
<< Previous
1
2
3
4
